Abstracts

A RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE RIFAMPIN FOR PULMONARY TUBERCULOSIS

The standard of care for patients with pulmonary tuberculosis is a 6-month, 4-drug regimen that includes rifampin throughout. This blinded, randomized, controlled Phase II clinical trial (ClinicalTrials.gov NCT01408914) systematically examined the concept that increased rifampin doses could shorten standard therapy for tuberculosis and improve treatment outcomes without increased toxicity. We randomized 180 adults with new,…

IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL

Among HIV-infected adults/children with CD4<100 cells/ul initiating ART in sub-Saharan Africa, the REALITY trial (ISRCTN43622374) showed that 12-week raltegravir (RAL)-intensified quadruple therapy resulted in significantly faster VL declines through 24 weeks, but did not reduce overall mortality or WHO 3/4 events compared to standard triple-drug ART. Integrase inhibitors may replace NNRTIs in first-line ART; there…

HAIR ANTIRETROVIRAL LEVELS STRONGLY PREDICT VIROLOGIC OUTCOMES IN ACTG’S A5257 TRIAL

AIDS Clinical Trials Group (ACTG) A5257 was a three-arm study comparing atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r) and raltegravir (RAL)-based regimens in naïve patients. The study showed similar rates of virologic success in all three arms, with RAL regimens better tolerated than protease inhibitor-regimens. Hair antiretroviral (ARV) levels reflect long-term exposure and have been associated with virologic…

MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV

MK-8591 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) in clinical development for the treatment of HIV-1 infection. MK-8591-triphosphate (MK-8591-TP), the active phosphorylated anabolite of MK-8591, exhibits a half-life of ~78-128 hours in human peripheral blood mononuclear cell (PBMCs). MK-8591 has been assessed in a monotherapy pharmacodynamic (PD) trial in treatment-naïve HIV-1-infected subjects, where single…

CHARACTERIZATION OF THE NEUTRALIZING ANTIBODY RESPONSE IN A LINKED HIV SUPERINFECTION

HIV-superinfection (HIV-SI) occurs when an infected individual acquires a new HIV strain that is phylogenetically distinct from their existing viral population. HIV-SI provides an opportunity to examine the potential role of pre-existing HIV-specific neutralizing antibodies (NAb) in protecting against a subsequent HIV challenge. Virally unlinked HIV+ individuals in monogamous (n=15) and polygamous relationships (n=6) from…